https://doi.org/10.4081/jbr.2011.4500

A murine model for virotherapy of malignant brain tumors

Vol. 84 No. 1 (2011)
Submitted: July 4, 2014
Accepted: July 4, 2014
Published: January 30, 2011
Glioma, HSV, HER-2
Abstract Views: 622
PDF: 383
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

E. Gambini
eleonora.gambini@gmail.com
E. Reisoli
I. Appolloni
L. Menotti
Paolo Malatesta
Glioblastomas (GBMs) are very aggressive and almost incurable brain tumors. The development of new therapeutical approaches capable of selectively killing cancer cells could represent a step forward to fight cancer. With this aim we tested the efficacy of a novel oncolytic therapy based on recombinant herpes simplex viruses (HSVs) infecting exclusively cells expressing the human receptor HER-2 [1, 2], overexpressed in about 15% of GBM model based on PDGF-B embryonic transduction [4, 5]. We engineered cell cultures derived from this model to express HER-2 and we injected intracranically such cultures in NOD/SCID mice. We evaluated the efficacy of R-LM113, a recombinant HSV directed to HER-2, in this glioma model expressing HER-2. We demostrated that mice injected with engineered glioma cells infected with R-LM113 developed glioma with a statistically significant delay compared to mice injected with non-infected engineered glioma cells.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

How to Cite

Gambini, E., Reisoli, E., Appolloni, I., Menotti, L., & Malatesta, P. (2011). A murine model for virotherapy of malignant brain tumors. Journal of Biological Research - Bollettino Della Società Italiana Di Biologia Sperimentale, 84(1). https://doi.org/10.4081/jbr.2011.4500

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.